BSE Live
Sep 08, 16:01Prev. Close
946.70
Open Price
927.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Sep 08, 15:58Prev. Close
946.50
Open Price
946.50
Bid Price (Qty.)
951.25 (4)
Offer Price (Qty.)
951.85 (4)
Key Financial Ratios of Alembic Pharmaceuticals (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
Per Share Ratios | ||||||
Basic EPS (Rs.) | 25.60 | 33.91 | 17.64 | 27.65 | 60.67 | |
Diluted EPS (Rs.) | 25.60 | 33.91 | 17.64 | 27.65 | 60.67 | |
Cash EPS (Rs.) | 39.69 | 47.70 | 31.53 | 42.15 | 67.56 | |
Book Value [ExclRevalReserve]/Share (Rs.) | 264.30 | 249.75 | 224.59 | 269.16 | 267.32 | |
Book Value [InclRevalReserve]/Share (Rs.) | 264.30 | 249.75 | 224.59 | 269.16 | 267.32 | |
Dividend / Share(Rs.) | 11.00 | 11.00 | 8.00 | 10.00 | 14.00 | |
Revenue from Operations/Share (Rs.) | 306.93 | 298.86 | 261.97 | 256.19 | 257.01 | |
PBDIT/Share (Rs.) | 48.30 | 52.40 | 33.98 | 48.84 | 80.49 | |
PBIT/Share (Rs.) | 34.20 | 38.60 | 20.09 | 34.34 | 72.72 | |
PBT/Share (Rs.) | 30.96 | 35.83 | 17.60 | 33.48 | 72.07 | |
Net Profit/Share (Rs.) | 25.60 | 33.91 | 17.64 | 27.65 | 59.80 | |
Profitability Ratios | ||||||
PBDIT Margin (%) | 15.73 | 17.53 | 12.97 | 19.06 | 31.31 | |
PBIT Margin (%) | 11.14 | 12.91 | 7.67 | 13.40 | 28.29 | |
PBT Margin (%) | 10.08 | 11.98 | 6.71 | 13.06 | 28.04 | |
Net Profit Margin (%) | 8.33 | 11.34 | 6.73 | 10.79 | 23.26 | |
Return on Networth / Equity (%) | 9.68 | 13.57 | 7.85 | 10.27 | 22.37 | |
Return on Capital Employed (%) | 12.54 | 14.96 | 8.62 | 12.28 | 25.28 | |
Return on Assets (%) | 6.65 | 10.41 | 5.65 | 7.68 | 17.34 | |
Total Debt/Equity (X) | 0.22 | 0.09 | 0.14 | 0.12 | 0.04 | |
Asset Turnover Ratio (%) | 0.86 | 0.94 | 0.78 | 0.73 | 74.54 | |
Liquidity Ratios | ||||||
Current Ratio (X) | 1.71 | 2.25 | 1.79 | 1.74 | 2.11 | |
Quick Ratio (X) | 0.81 | 1.23 | 0.97 | 0.85 | 0.94 | |
Inventory Turnover Ratio (X) | 1.00 | 1.07 | 0.94 | 0.83 | 3.84 | |
Dividend Payout Ratio (NP) (%) | 42.97 | 23.59 | 56.68 | 50.62 | 0.00 | |
Dividend Payout Ratio (CP) (%) | 27.71 | 16.77 | 31.71 | 33.21 | 0.00 | |
Earnings Retention Ratio (%) | 57.03 | 76.41 | 43.32 | 49.38 | 0.00 | |
Cash Earnings Retention Ratio (%) | 72.29 | 83.23 | 68.29 | 66.79 | 0.00 | |
Valuation Ratios | ||||||
Enterprise Value (Cr.) | 19,385.78 | 19,701.64 | 10,354.51 | 15,179.32 | 19,108.71 | |
EV/Net Operating Revenue (X) | 3.21 | 3.35 | 2.01 | 3.01 | 3.78 | |
EV/EBITDA (X) | 20.42 | 19.13 | 15.50 | 15.81 | 12.08 | |
MarketCap/Net Operating Revenue (X) | 3.03 | 3.29 | 1.89 | 2.89 | 3.76 | |
Retention Ratios (%) | 57.02 | 76.40 | 43.31 | 49.37 | 0.00 | |
Price/BV (X) | 3.52 | 3.93 | 2.21 | 2.75 | 3.61 | |
Price/Net Operating Revenue | 3.03 | 3.29 | 1.89 | 2.89 | 3.76 | |
Earnings Yield | 0.03 | 0.03 | 0.04 | 0.04 | 0.06 |
12.08.2025
Alembic Pharma Consolidated June 2025 Net Sales at Rs 1,710.72 crore, up 9.54% Y-o-Y
05.08.2025
Alembic Pharma Standalone June 2025 Net Sales at Rs 1,494.17 crore, up 1.26% Y-o-Y
06.05.2025
Alembic Pharma Consolidated March 2025 Net Sales at Rs 1,769.64 crore, up 16.66% Y-o-Y
06.05.2025
Alembic Pharma Standalone March 2025 Net Sales at Rs 1,570.64 crore, up 6.52% Y-o-Y
19.10.2021
Alembic Pharma Q2 PAT may dip 49.2% YoY to Rs 169.4 cr: ICICI Direct
13.07.2021
Alembic Pharmaceuticals Q1 PAT may dip 28.7% YoY to Rs 215 cr: KRChoksey
12.07.2021
Alembic Pharma Q1 PAT may dip 20.3% YoY to Rs 240.2 cr: ICICI Direct
18.01.2021
Alembic Pha Q3 PAT seen up 19.9% YoY to Rs. 280.9 cr: ICICI Direct